PTN

PALATIN TECH
AMEX

实时行情|Nasdaq Last Sale

0.4184
+0.0015
+0.36%
已收盘, 17:58 04/03 EDT
开盘
0.4300
昨收
0.4169
最高
0.4300
最低
0.3900
成交量
77.24万
成交额
--
52周最高
1.780
52周最低
0.3550
市值
9,591.43万
市盈率(TTM)
2.999
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTN价格均价为2.167,最高价位3.000,最低价为1.500。

EPS

PTN 新闻

更多
  • 为美元续命,美联储干了这件大事!
  • 新浪财经-自媒体综合 · 1小时前
  • 债务危机幽灵再现,激进放水后美联储或只剩一个策略
  • 新浪财经综合 · 1小时前
  • 德国今年经济或因疫情萎缩3-6%
  • 新浪财经 · 2小时前
  • 土豪国也撑不住:迪拜最大地产公司全员减薪
  • 新浪财经 · 2小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

PTN 简况

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). MC4r is a compound used for treatment of obesity and diabetes. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications.
展开

微牛提供Palatin Technologies, Inc.(AMEX-PTN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTN股票新闻,以帮助您做出投资决策。